Update: Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating

12:05 PM EDT, 10/01/2026 (MT Newswires) -- (Updates to include Wedbush's commentary). Wedbush raised its price target on Shattuck Labs (STTK) to $14 from $11, while reiterating its outperform rating. The firm's planned initiation of the Phase 2 RECEPTIVE-HS1 trial of SL-325 in participants with moderate-to-severe hidradenitis suppurativ later this year, expanding development of its DR3-blocking antibody beyond IBD. The decision follows positive tulisokibart data presented by Merck at EADV. The brokerage views the decision positively, describing it as a logical expansion of SL-325 into an indication where the TL1A/DR3 pathway has direct clinical validation. Shattuck Labs has an average rating of buy and mean price target of $15.25, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) Price: 7.19, Change: +0.36, Percent Change: +5.35